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Abstract
Multiple sclerosis represents the world’s most common cause of neurological disability in young 
people and is attributed to a loss of immune tolerance toward proteins of the myelin sheath. 
Typical treatment options for MS patients involve immunomodulatory drugs, which act non-
specifically, resulting in global immunosuppression. The study discussed herein aims to 
demonstrate the efficacy of antigen-specific immunotherapies involving conjugation of disease 
causing auto-antigen, PLP139–151, and a potent immunosuppressant, dexamethasone. Antigen-
drug conjugates (AgDCs) were formed using copper-catalyzed azide-alkyne cycloaddition 
chemistry with the inclusion of a hydrolyzable linker to maintain activity of released 
dexamethasone. Subcutaneous administration of this antigen-drug conjugate to SJL mice induced 
with experimental autoimmune encephalomyelitis protected the mice from symptom onset 
throughout the 25-day study, demonstrating enhanced efficacy in comparison to dexamethasone 
treatment. These results highlight the benefits of co-delivery of auto-antigens with 
immunosuppressant drugs as AgDCs for the treatment of autoimmune diseases.
Graphical Abstract
*To whom correspondence should be addressed: University of Kansas, 2030 Becker Drive, Lawrence, KS 66047. Phone: (785) 
864-1455, Fax: (785) 864-1454, berkland@ku.edu.
‡Authors contributed equally to this work
Supporting Information
Figure S1. HSQC NMR data for DEX-N3. Figure S2. Levels of IFN-γ at peak of disease. Figure S3. Levels of IL-6 at peak of disease. 
Figure S4. Levels of IL-15 at peak of disease. Figure S5. Levels of IL-17A at peak of disease. Figure S6. Levels of IL-21 at peak of 
disease. Figure S7. Levels of IL-23 at peak of disease. Figure S8. Levels of TNF-α at peak of disease.
HHS Public Access
Author manuscript
Mol Pharm. Author manuscript; available in PMC 2020 October 27.
Published in final edited form as:














Autoimmunity; antigen-specific immunotherapy; copper-catalyzed azide-alkyne cycloaddition; 
experimental autoimmune encephalomyelitis; antigen-drug conjugate
Introduction
The adaptive immune response is dependent on recognition of target antigens, and 
autoimmune diseases occur when the body fails to maintain tolerance toward self-antigens.1 
These self-antigens can be present in a number of host tissues in various organs, leading to 
many types of autoimmune diseases including multiple sclerosis (MS).2 MS is the most 
common cause of neurological disability in young adults, affecting approximately 2.5 
million patients worldwide3, and symptoms of the disease are highly variable4 While the 
mechanisms of disease induction have not been fully elucidated, a prevailing hypothesis is 
that loss of immune tolerance towards proteins composing the myelin sheath, such as 
proteolipid protein (PLP) and myelin basic protein (MBP), triggers recruitment of offending 
myelin-specific CD4+ T cells, resulting in demyelination within the central nervous system.5 
Current therapies include monoclonal antibodies and corticosteroids, however, the treatment 
landscape for MS is expanding as our understanding of disease pathogenesis continues to 
evolve.6 Corticosteroids have been a cornerstone for MS therapy, but the lack of specificity 
results in a wide range of side effects. Attempts have been made to develop antigen-specific 
immune therapies (ASITs) to reduce side effects and selectively re-tolerize the immune 
system to myelin sheath proteins. Despite being relatively safe, ASITs have yet to reduce the 
severity of MS.7–9 Here, we present antigen-drug conjugates (AgDCs) as a combination of 
these approaches with the potential to boost the efficacy of ASIT while mitigating the 
detrimental side effects of current immunosuppressant therapies.
AgDCs merge two general approaches to combat autoimmunity: immunomodulatory agents 
and ASIT. ASIT provides the specificity necessary to reverse an immune response toward a 
particular antigen. ASIT has been effective for inducing tolerance towards allergens, but has 
yet to emerge as an effective autoimmune therapy.7–9 Immunomodulatory agents can 
effectively treat autoimmune diseases, but suffer from systemic exposure and subsequent 
global immunosuppression, which can be problematic in immunocompromised patient 
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populations by increasing vulnerability to opportunistic infections. By chemically 
conjugating the antigen and immunomodulator, the antigen may target the 
immunomodulator to diseased cell populations, potentially limiting off-target side effects. 
The concept of AgDCs is similar to antibody-drug conjugates (ADCs), however AgDCs 
likely achieve high affinity specificity by targeting endogenous autoantibodies or cognate B 
cell receptors, thus essentially flipping the mechanism of ADCs.
The design of AgDCs requires selection of an appropriate antigen or epitope, an immune 
modulator, and a linking scheme. With this in mind, a murine experimental autoimmune 
encephalomyelitis (EAE) model exhibiting clinical and histopathological similarities to 
relapsing-remitting multiple sclerosis (RRMS) in humans2 was selected to probe the 
proposed AgDC concept. The model is induced by administering an adjuvanted ‘vaccine’ 
containing the antigenic epitope PLP139–151. This particular EAE model is CD4+ T cell-
mediated disease with B cell involvement, leading to primary demyelination of the axonal 
tracks in the CNS and subsequent progressive paralysis of the hind-limbs.10–11 Most 
importantly, this particular EAE model provided a simplified system for testing the efficacy 
of AgDCs wherein the disease may be induced with a specific peptide, PLP139–151, and 
subsequently treated with an AgDC utilizing the same PLP139–151 epitope.
Dexamethasone (DEX) was selected as the immune modulator for testing the AgDC 
concept. Our lab previously screened multiple immune modulators in combination with 
PLP139–151 by using splenocytes derived from EAE mice.12 DEX emerged as one of the 
most potent suppressors of proinflammatory cytokines when rechallenging EAE splenocytes 
with PLP139–151 and also showed evidence of inducing markers of immune tolerance (e.g. 
upregulation of IL-10). DEX possesses the necessary potency required (pMol-nMol 
range)13–14, since the dose typically used for antigen-specific immunotherapy is on the order 
of milligrams of antigen per injection.15 Finally, we rationalized DEX must be released in 
order to escape the typical binding and internalization pathway associated with antigen 
recognition and processing. Thus, we designed an ester linker capable of releasing DEX 
from PLP139–151 via hydrolysis with accelerated release under acidic conditions.
In this article, we outline the synthetic strategy, characterization, and biological screening of 
an AgDC containing PLP139–151 and DEX. These two components were conjugated 
utilizing copper-catalyzed azide-alkyne cycloaddition (CuAAC) and this linkage was 
characterized by HPLC and mass spectrometry. Additionally, AgDC linker stability was 
monitored over a short time frame to confirm the desired release of DEX. Finally, the 
efficacy of this AgDC was demonstrated first in vitro through the use of EAE splenocytes 
induced against PLP139–151 and subsequently in vivo through subcutaneous administration 
to EAE mice.
Materials and Methods
DEX, tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), and sodium ascorbate (NaAsc) 
were purchased from Sigma-Aldrich (St. Louis, MO). Copper(II) sulfate pentahydrate 
(CuSO4 • 5H2O) was purchased from Acros Organics (Geel, Belgium). 2,5-
dioxopyrrolidin-1-yl 2-azidoacetate, DBCO-PEG4-Maleimide, DBCO-NH2, and MMAE-
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DBCO were purchased from Click Chemistry Tools, LLC (Scottsdale, AZ). Doxorubicin 
hydrochloride was purchased from LC Laboratories (Woburn, MA). Mertansine (DM1) was 
purchased from Carbosynth Limited (Berkshire, UK). All other chemicals and reagents were 
analytical grade and were used as received without further purification.
The peptides PLP139–151-Alk and PLP139–151-N3 have been synthesized in our laboratory 
via solid phase peptide synthesis on a Wang resin, but larger quantities of each peptide were 
obtained from Biomatik Corporation (Wilmington, DE). In each case, the linker 3-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)propanoic acid was purchased from PurePEG, LLC (San Diego, 
CA) and 4-pentynoic acid was purchased from Sigma-Aldrich (St. Louis, MO).
Synthesis of azide-functionalized DEX (DEX-N3)
DEX was added to a flame dried 250 mL round bottom flask with a stir bar and septa. 
Anhydrous MeCN was added under nitrogen, then DIPEA via glass syringe. The flask was 
stirred for 10 min before azidoacetic acid NHS ester was added as a powder. The reaction 
mixture was stirred overnight at room temperature before being analyzed by HPLC. 
Additional equimolar aliquots of azidoacetic acid NHS ester were added, followed by 
stirring for 2 hours at room temperature and analyzing by HPLC, until no additional benefit 
was observed. The crude reaction mixture was evaporated under reduced pressure, then 
dissolved in 4:6 MeCN:H2O and purified by prep HPLC. The resulting column fractions 
were evaporated under reduced pressure to yield the final product as a white powder. 1H 
NMR (500 MHz, DMSO-d6) δ 7.30 (d, J = 10.2 Hz, 1H), 6.23 (dd, J = 10.1, 1.9 Hz, 1H), 
6.01 (t, J = 1.7 Hz, 1H), 5.45 (dd, J = 5.0, 1.4 Hz, 1H), 5.23 (s, 1H), 5.17 (d, J = 17.5 Hz, 
1H), 4.90 (d, J = 17.6 Hz, 1H), 4.32 – 4.19 (m, 2H), 4.19 – 4.11 (m, 1H), 2.88 (dqd, J = 11.5, 
7.2, 4.1 Hz, 1H), 2.62 (tdd, J = 13.6, 6.0, 1.7 Hz, 1H), 2.44 – 2.32 (m, 1H), 2.35 – 2.28 (m, 
1H), 2.22 – 2.05 (m, 3H), 1.77 (dt, J = 11.2, 5.2 Hz, 1H), 1.70 – 1.58 (m, 1H), 1.56 (dd, J = 
13.8, 2.0 Hz, 1H), 1.49 (s, 3H), 1.35 (qd, J = 12.9, 5.0 Hz, 1H), 1.08 (ddd, J = 12.1, 8.2, 4.1 
Hz, 1H), 0.89 (s, 3H), 0.80 (d, J = 7.2 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 204.36, 
185.30, 168.28, 167.10, 152.77, 129.03, 124.12, 102.00, 100.61, 90.52, 70.63, 70.34, 69.00, 
49.34, 48.09, 48.05, 47.87, 43.33, 35.69, 35.53, 33.67, 33.51, 31.92, 30.28, 27.32, 23.03, 
22.98, 16.31, 15.15, 1.19.Expected [M+H]+ = 476.2191 Da, Observed [M+H]+ = 476.2067 
Da.
Synthesis of PLP139–151-DEX
To a solution of PLP139–151-Alk (93.6 μmol) in 120 mL deionized H2O was added DEX-
N3 (189.4 μmol, 2.02 eq.) in 12 mL EtOH. 5.7 mL of a premixed solution of CuSO4•5H2O 
(38.1 μmol) and THPTA (189.8 μmol) in deionized H2O was added to the reaction mixture, 
followed by 7.2 mL of NaAsc (726.9 μmol) in deionized H2O. The reaction was allowed to 
stir at room temperature for 1 hour before an aliquot was removed for analytical HPLC to 
monitor reaction progress. After 3 hours, the reaction mixture was concentrated under 
reduced pressure, and purified by preparative HPLC on a Waters XBridge BEH C18, 5 μm, 
130 Å, 19×250 mm column using a gradient of MeCN in H2O (constant 0.05% TFA). The 
isolated fractions were evaporated under reduced pressure to remove residual MeCN, then 
frozen at −20°C and lyophilized to yield a white powder. Expected [M+2H]2+ = 1039.5224 
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Da, [M+3H]3+ = 693.3507 Da; Observed [M+2H]2+ = 1039.5145 Da, [M+3H]3+ = 693.3478 
Da.
Analytical characterization
All HPLC chromatographic analysis was conducted on a Waters Alliance HPLC system 
equipped with either a diode array detector or dual wavelength UV/Vis detector. For RP-
HPLC, general chromatographic conditions employed a linear elution gradient from 5–95% 
acetonitrile in water (constant 0.05% trifluoroacetic acid) over 50 min, on a Waters XBridge 
BEH C18, 3.5 μm, 130 Å stationary phase (4.6 × 150 mm), with a 1.0 mL/min flow rate and 
a 35°C column temperature. For semi-preparative HPLC, a linear elution gradient of 
acetonitrile in water (constant 0.05% trifluoroacetic acid) over 20 min, on a Waters XBridge 
BEH C18, 5 μm, 130 Å stationary phase (19 × 250 mm), with a 14.0 mL/min flow rate. 
Gradients were optimized for each run using the identical stationary phase in a 4.6 × 250 
mm configuration.
LC/MS sample analysis was completed on a Waters Xevo G2, employing linear elution 
gradients of 15–100% acetonitrile in water (constant 0.1% formic acid) over 45 min, on a 
Waters XBridge BEH C18, 1.7 μm, 130 Å stationary phase (0.075 × 250 mm), with a 0.5 
μL/min flow rate and 50°C column temperature. Electrospray ionization, operating in the 
positive mode (ESI+), was used as the ionization source with a QTOF mass analyzer used 
for detection.
NMR spectra were collected on a Bruker Avance AVIII 500 MHz spectrometer equipped 
with a dual carbon/proton cryoprobe, and all samples were dissolved in 650 μL of D2O or 
DMSO-d6. Data processing was completed using MestReNova 11.0 (Santiago de 
Compostela, Spain).
Drug release and stability studies
Release and stability studies were conducted via HPLC with UV detection by dissolving the 
compound of interest in various buffers (typically pH 7.0 phosphate, pH 5.5 acetate, 
deionized H2O, etc.) and evaluating the release at temperatures and times relevant to the 
particular study. Peak integration is used for quantification, accounting for initial purity of 
the PLP-DEX at T = 0.
Induction of EAE
In vitro and in vivo studies were performed through the use of 4–6 week old SJL/J (H-2) 
female mice purchased from Envigo Laboratories (Indianapolis, IN). All experiments were 
approved through the University’s Institutional Animal Care and Use Committee with 
animal housing in pathogen-free conditions. An emulsion containing 200 μg PLP139–151 in 
Complete Freund’s Adjuvant (CFA) was prepared by combining IFA and heat-killed M. 
Tuberculosis strain H37RA at a final concentration of 4 mg/mL with subsequent 
emulsification between CFA and PBS containing 200 μg PLP139–151. This PLP in CFA 
emulsion was administered to mice on day 0 through four subcutaneous injections of 50 μL 
each located above each shoulder and hind flank for a total of 0.2 mL. Additionally, 
intraperitoneal injections of pertussis toxin (100 ng in 100 μL PBS) were administered on 
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day 0 and day 2. Disease severity was recorded using the following clinical scoring system: 
0, no clinical disease symptoms; 1, weakness or limpness of the tail; 2, weakness or partial 
paralysis of one or two hind limbs (paraparesis); 3, full paralysis of both hind limbs 
(paraplegia); 4, paraplegia plus weakness or paralysis of forelimbs; 5, moribund (euthanasia 
necessary). Mouse body weight was also recorded daily throughout the duration of the 
studies.
In Vivo Efficacy in EAE Mice
In vivo studies were performed with 9 mice per treatment group. Five mice were euthanized 
on day 14 (peak-of-disease) while the remaining mice were euthanized on day 25. 
Treatments were administered to mice through subcutaneous injection of 100 μL at the base 
of the neck on the back of the mouse on days 4, 7, and 10 following EAE induction. All 
treatments were dosed at a 200 nmol DEX basis in 40 mg/mL mannitol as vehicle. Mice 
were weighed daily from day 0 and scored daily from day 7 until the end of the study at day 
25.
Splenocyte Isolation
Spleens were harvested from EAE and healthy control mice on peak-of-disease or day 25 for 
in vitro and in vivo studies, respectively. Spleens were placed in 5 mL of RPMI 1640 
containing L-glutamine and 1% Penicillin-Streptomycin and placed on ice for transportation. 
The spleens were pressed through sterile wire mesh with the use of a rubber 1 mL syringe 
plunger and the cellular extract was collected and centrifuged at 1100xg for 5 minutes. In 
order to lyse red blood cells the cell pellet was resuspended in 5 mL of Gey’s lysis solution 
for 5 minutes on ice. Quenching of the lysis solution was performed by adding 10 mL of 
RPMI 1640 supplemented with L-glutamine, 1% Penicillin-Streptomycin, and 10% fetal 
bovine serum (FBS) (complete RPMI, cRPMI). Cells were centrifuged at 1100xg for 5 
minutes and resuspended in cRPMI prior to counting in 0.04% trypan blue. Cultures with in 
vitro treatments or PLP rechallenge were kept at 37°C and 5% CO2.
Cell Metabolic Assay
Cellular metabolism was determined through the use of resazurin. Splenocytes were 
incubated with 75 μmol/L resazurin for 3 hours. Change in fluorescence (ex 560/em 590) 
provides a measurement of metabolic reductive capacity. Results for in vitro treated samples 
were normalized against untreated controls and background fluorescence was subtracted 
from all samples through fluorescence measurements on cRPMI containing resazurin. These 
readings were performed using a Spectramax M5 (Molecular Devices) plate reader.
Cytokine Response
Following the day 14 and day 25 splenocyte harvests from in vivo studies, in vitro 
splenocyte supernatants were collected after 96 hours incubation with PLP. Incubation was 
performed at 1×106 cells/well in 96 well plates in the presence or absence of 25 μM PLP. 
The secretion of GM-CSF, IFN-γ, TNF-α IL-2, IL-6, IL-10, IL-15, IL-17, IL-21, and IL-23 
was measured using a U-Plex kit following manufacturer instructions (Meso Scale 
Discovery).
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Statistical analysis of data was performed using two-way analysis of variance (ANOVA) and 
Tukey multiple comparison tests. IC50 studies were analyzed using a 4PL-sigmoidal 
function. Criteria for significance are as follows: * p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001. For Figure 7 and Figure 9 significant differences between the PLP and DEX 
mixture and mannitol vehicle control are denoted by # p<0.05. All statistical analysis was 
performed using GraphPad Software (GraphPad Software Inc.).
Results
Analytical characterization of chemical entities
The constituent and conjugate molecules can be characterized by traditional chemical 
methods, including NMR, HPLC, LC/MS, and other spectroscopic means to confirm the 
structure of the entity. HPLC analysis of PLP-Dex with UV/Vis detection provides typical 
purity values in excess of 93% following preparative HPLC purification (Figure 2). A 
similar analysis by LC-MS corroborates these results, showing a mass shift in the final 
conjugate indicative of attachment of DEX to PLP (Figure 3). From an NMR perspective, an 
added benefit to installing the alkyne linker on PLP is the presence of a distinct resonance in 
1H/13C heteronuclear single quantum coherence (HSQC) experiment, corresponding to the 
terminal alkyne correlation (δ(1H) ≈ 2.3ppm, δ(13C) ≈ 70 ppm) which is present in a unique 
chemical environment and well separated from other signals (Figures 4 and S1). After 
conjugation, this resonance undergoes a significant downfield shift (δ(1H) ≈ 7.8ppm) as it is 
incorporated as part of the conjugated triazole ring system (Figure 4). One additional 
advantage of conjugating hydrophobic drug molecules to hydrophilic peptides is the impact 
on aqueous solubility. The PLP139–151 peptide is soluble in excess of 60 mg/mL, providing 
a significant enhancement in drug solubility in the resulting amphiphilic conjugates.
Conjugate stability and drug release kinetics
PLP-DEX contains an acid-labile ester linkage capable of releasing the unadulterated parent 
drug in acidic microenvironments present inside cells. A study of the release kinetics (Figure 
5) indicated DEX is released over greater than 100 hours in unbuffered solutions and is 
released completely over approximately 50 hours when in acidic conditions (pH 5.5). 
Interestingly, complete hydrolysis of the linker occurs in a few hours when in phosphate 
buffered solutions, indicating that phosphate anions catalyze the release of DEX from PLP, 
likely through nucleophilic attack on the ester bond. Due to this finding, in vivo 
administration of PLP-DEX was carried out in 40 mg/mL mannitol to prevent hydrolysis 
prior to injection.
IC50 determination of conjugates and payload
In order to determine the impact of the CuAAC chemical linkage on the activity of esterified 
DEX, EAE splenocytes harvested at peak of disease (Day 12) were isolated and treated with 
DEX or PLP-DEX over a range of concentrations. After 120 hours, a resazurin assay was 
performed to assess cellular metabolism and these data were normalized to untreated EAE 
splenocytes (Figure 6). These data provide calculated IC50s for DEX and PLP-DEX of 6.84 
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+/− 4.18 nM and 7.55 +/− 2.80 nM, respectively. This result indicates that DEX maintains 
activity after release from the AgDC and demonstrates the rapid release of DEX from the 
acid-labile ester linkage in an in vitro setting, as evidenced by the similar IC50 values 
obtained for the free drug and the AgDC.
In vivo screening of conjugates
In vivo efficacy of PLP-DEX in the treatment of EAE was determined through subcutaneous 
administration of the conjugate as well as component treatments at a dose equivalent to 200 
nmol DEX. Treatments were administered in 40 mg/mL mannitol on days 4, 7, and 10 with 
n=9 prior to day 14 and n=4 after day 14. Five mice in each treatment group were chosen at 
random and euthanized at peak of disease in order to assess splenocyte response to 25 μM 
PLP rechallenge. This in vivo schedule allows for determination of the effectiveness of 
AgDCs in ameliorating EAE clinical symptoms as well as mechanistic insight into changes 
in cellular expression after treatment.
In vivo clinical score data indicates the importance of conjugation of DEX to the antigen of 
interest (Figure 7). EAE mice treated with the AgDC demonstrated no clinical symptoms 
throughout the 25 day study (Figure 7B). This represents a vast improvement over the free 
drug, DEX (Figure 7A), which appears to have no clinical effect in the EAE model at a 200 
nmol dose. Similar to the AgDC, administration of a combination of the components, PLP 
and DEX, ameliorates symptoms and appears to delay the onset of paralysis in EAE mice 
(Figure 7B); however, this co-administration is less effective than co-delivery through direct 
conjugation. Additionally, co-administration of PLP and DEX as a mixture resulted in 
delayed symptom onset in those mice which developed disease (Table 1). Treatment with 
individual components, PLP or DEX, had no significant effect in reducing EAE symptoms 
(Figure 7A). Similar trends are observed in animal weight data (Figure 9), in which weight 
gain is associated with a healthy mouse and weight loss correlates to symptom severity. In 
combination therapies (Figure 9B), continuous weight gain is observed throughout the 
duration of the study. Conversely, mice treated with individual components as well as 
mannitol (Figure 9A) displayed significant weight loss leading up to disease remission.
As previously stated, 5 mice were euthanized on day 14 in order to assess cellular 
differences due to the various in vivo treatments (Figures 10 and S2–S8). Of note, at day 14 
a small but significant reduction in GM-CSF (Figure 10A), an inflammatory cytokine, was 
observed for combination therapies. Additionally, detection of IL-2 (Figure 10B), a cytokine 
associated with T-cell proliferation, was greatly diminished in combination therapies as well 
as the PLP control. These results demonstrate the early immunosuppressive effects of 
combination treatments containing DEX. Comparisons of GM-CSF and IL-2 between the 
mixture of PLP and DEX and the AgDC revealed no significant differences between co-
administration and co-delivery at this stage of treatment. One notable difference between 
these treatment groups in cytokine expression was observed in IL-10 (Figure 10C), in which 
the mixture treatment group experienced a significant reduction in IL-10 expression 
compared to control. This result was not observed in the conjugate treatment group and may 
account for the differences in efficacy observed in vivo by maintaining an anti-inflammatory 
effector cell population. Numerous other cytokines were analyzed; however, no significant 
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changes associated with treatment efficacy were observed in the expression of these 
cytokines (Figures S2–S8).
Discussion
Clinical researchers attempting to treat autoimmune diseases such as MS have historically 
focused on either administering drugs to suppress and/or modulate the immune response 
(e.g. classic immunosuppression) or, more recently, ASIT (e.g. long treatment regimens of 
low doses of antigen or altered antigen analogs).16 Currently, potent immunomodulatory 
drugs represent the core treatment options for MS patients, but these drugs act in a non-
specific manner and may eliminate or suppress healthy immune cell populations. 
Conversely, although ASIT is relatively safe, this approach has not yielded sufficient 
efficacy to suppress autoimmunity.7–9 Through direct conjugation of potent 
immunomodulators to self-antigens, targeted immunosuppression of self-reactive 
populations may boost the efficacy of ASIT and diminish the side effects associated with 
immunosuppressants.
The encephalitogenic peptide selected as the targeting moiety is a portion of the intracellular 
loop17 of the full-length transmembrane protein, PLP139–151. Previous studies have shown 
the impact of PLP139–151 sequence variability on TCR binding affinity18, highlighting the 
influence of side chain interactions in the major histocompatibility class 2 binding pocket. 
Therefore, disrupting interactions through traditional synthetic methods targeting side chain 
residues of the native sequence were hypothesized to alter conjugate binding and/or uptake. 
To circumvent these potential deleterious effects, all modifications to the targeting antigen 
occurred through the N-terminal amino acid and were installed via heterobifunctional linkers 
as the final step of solid-phase peptide synthesis, prior to cleavage from the resin. Linker 
length, flexibility, and stability were key AgDC design considerations. The overarching 
strategy utilizing copper-catalyzed azide alkyne cycloaddition (CuAAC) enabled rapid and 
efficient synthesis of PLP-DEX (Figure 2) and related conjugates.
Data reported here support a growing base of literature highlighting the benefits of 
delivering auto-antigen alongside immunomodulators. Although historically categorized as 
an immunosuppressant, DEX is now known to skew cellular responses towards immune 
tolerance via multiple mechanisms.19–22 For example, DEX was shown to enhance CTLA-4 
expression during T cell activation, thus countering the typical B7/CD28 pro-inflammatory 
costimulatory signal.22 DEX also inhibited IL-12 secretion by dendritic cells and increased 
FoxP3 expression in naïve T lymphocyte co-cultures.20 DEX was reported to induce 
expression of indoleamine 2–3 dioxygenase (IDO), an enzyme implicated in T cell 
tolerance21 has been used to create ‘tolerogenic dendritic cells’ (defined as high TLR-2, 
CXCR4, and CCR7 expression levels) from healthy donors.19
Because of these pluripotent mechanisms, some have tested DEX as an adjuvant that can be 
co-administered along with antigen as a means to induce antigen-specific immune tolerance.
20, 23–24 Previously, Kang and colleagues demonstrated desensitization specific to OVA323–
339 peptide after co-administration of this peptide alongside DEX.25 Additionally, applying 
this strategy of co-administration to the NOD autoimmune diabetes model protected nearly 
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all mice from disease induction throughout the study period, suggesting these therapies may 
be adapted for application to numerous autoimmune diseases with known auto-antigens.25 
Further development of this treatment strategy by Peine et al. utilized acetalated dextran 
particles as a co-delivery vehicle for a myelin oligodendrocyte glycoprotein (MOG) peptide 
and DEX in EAE, and administration of these microparticles to EAE mice after disease 
onset resulted in significant reduction in disease severity when both components were 
present.26 With such striking differences in vivo between combination therapies and free 
DEX, our findings highlight the advantages associated with delivery of an 
immunosuppressive drug in the context of the auto-antigens of interest. Furthermore, 
conjugation of DEX to PLP139–151 may maximize co-delivery of auto-antigen and 
immunomodulator in larger organisms, enhancing drug potency as demonstrated and 
potentially limiting off-target effects.
Conclusions
Antigen-drug conjugates (AgDCs) represent a novel class of therapeutics with broad 
applicability to a variety of antigen-specific autoimmune disorders. By combining the 
benefits of two traditional treatment approaches, ASIT and immunomodulatory therapy, 
AgDCs employ a synergistic approach by conjugating the antigen to the immunomodulatory 
agent. The enhanced specificity associated with therapeutics of this class may help to 
minimize global immunosuppression often observed with immunomodulatory small 
molecule treatments. This publication serves as an introduction to the modular synthetic 
design achieved in our lab and demonstrates both efficacy and safety of in vivo AgDC 
treatment in a mouse model of MS with which the autoreactive antigen is identified. The 
EAE model provides a valuable system for the initial testing of AgDCs as induction and 
treatment of the disease can be achieved utilizing a single antigen epitope, in this case 
PLP139–151. Subcutaneous treatment with free DEX at a 200 nmol dose appears to have 
little effect compared to control on modifying the disease course. EAE mice treated in vivo 
with PLP-DEX; however, demonstrated no onset of disease over a 25 day period and 
appeared healthy throughout the study, which demonstrates the efficacy achievable with co-
delivery of the antigen and immunomodulator. The modular fashion of this AgDC approach, 
coupled with the consistency and specificity of the chemistries employed, make AgDCs a 
potential disease-specific therapeutic class for autoimmune disorders.
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(A) Reaction scheme for the synthesis of DEX-N3. (B) Reaction scheme for the synthesis of 
PLP-DEX. (C) Degradation of PLP-DEX to release parent drug, DEX.
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Representative analytical HPLC chromatogram showing the starting materials, PLP-Alk, and 
DEX-N3, along with the purified reaction product, PLP-DEX.
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Representative mass spectral characterization showing multiple charge states of the starting 
peptide and the antigen-drug conjugate, PLP-DEX.
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1H/13C HSQC NMR data for PLP139–151-Alk (top) and PLP139–151-DEX (bottom).
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Release of DEX from PLP139–151-DEX as a function of time and buffer, at 37°C. Starting 
peptide concentration was 1 mg/mL, corrected for potency, and quantified via linear 
calibration curve.
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Resorufin fluorescence of EAE splenocytes treated with free DEX or PLP-DEX for 120 
hours (n=6). These data are normalized to untreated EAE splenocytes. Calculated IC50s for 
these treatments are 6.84 +/− 4.18 nM and 7.55 +/− 2.80 nM for DEX and PLP-DEX, 
respectively. Reported values are with standard error.
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Clinical score data for EAE mice treated in vivo with (A) free DEX and free PLP139–151 as 
well as (B) a mixture of free DEX and PLP139–151 and the PLP-DEX conjugate. 
Treatments were administered subcutaneously on days 4, 7, and 10 at doses of 200 nmol 
DEX basis. N=9 until day 14 and n=4 after day 14. Five mice were chosen at random from 
each group on day 14 for euthanasia in order to assess splenocyte differences in treatment 
groups around peak of disease. Data provided is mean ± SD. *p<0.05 for Mannitol vs PLP-
DEX and # p<0.05 for Mannitol vs PLP and DEX Mix.
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Percent disease incidence for all treatment groups where disease onset is characterized by a 
c.s. ≥ 1. N=9 until day 14 and n=4 after day 14. Five mice were chosen at random from each 
group on day 14 for euthanasia in order to assess splenocyte differences in treatment groups 
around peak of disease.
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Mouse weight data for EAE mice treated in vivo with (A) free DEX and free PLP139–151 
as well as (B) a mixture of free DEX and PLP139–151 and the PLP-DEX conjugate. Data 
are normalized to the individual mouse weight at day 8 (symptom onset). Treatments were 
administered subcutaneously on days 4, 7, and 10 at doses of 200 nmol DEX basis. N=9 
until day 14 and n=4 after day 14. Five mice were chosen at random from each group on day 
14 for euthanasia in order to assess splenocyte differences in treatment groups around peak 
of disease. *p<0.05 for Mannitol vs PLP-DEX and # p<0.05 for Mannitol vs PLP and DEX 
Mix.
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Levels of (A) GM-CSF (B) IL-2 and (C) IL-10 were observed at peak of disease (day 14) 
after isolated splenocytes from in vivo treated mice were incubated for 96 hours with 25 μM 
PLP. N=5, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001
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Table 1:
Disease incidence rate and mean day of disease onset ± SD for each treatment group. Incidence rate is 
represented as a fraction of total mice per treatment group with clinical score ≥ 1. Mean day of onset is 
calculated only for symptomatic animals.
Mannitol DEX PLP PLP and DEX mix PLP-Dex
IncidenceRate(Fraction) 9/9 9/9 5/9 2/9 0/9
Mean Day of Onset ± SD 10.8 ± 1.1 12.6 ± 1.3 11.4 ± 1.5 15.5 ± 2.1 -
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